Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy—let’s define who benefits the most
@article{TLCR96694,
author = {Eric Santoni-Rugiu and Jens Benn Sørensen and Edyta Maria Urbanska},
title = {Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy—let’s define who benefits the most},
journal = {Translational Lung Cancer Research},
volume = {14},
number = {2},
year = {2025},
keywords = {},
abstract = {},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/96694}
}